Chand Khanna, Timothy M Fan, Richard Gorlick, Lee J Helman, Eugenie S Kleinerman, Peter C Adamson, Peter J Houghton, William D Tap, Danny R Welch, Patricia S Steeg, Glenn Merlino, Poul H B Sorensen, Paul Meltzer, David G Kirsch, Katherine A Janeway, Brenda Weigel, Lor Randall, Stephen J Withrow, Melissa Paoloni, Rosandra Kaplan, Beverly A Teicher, Nita L Seibel, Malcolm Smith, Aykut Uren, Shreyaskumar R Patel, Jeffrey Trent, Sharon A Savage, Lisa Mirabello, Denise Reinke, Donald A Barkaukas, Mark Krailo, Mark Bernstein
Despite successful primary tumor treatment, the development of pulmonary metastasis continues to be the most common cause of mortality in patients with osteosarcoma. A conventional drug development path requiring drugs to induce regression of established lesions has not led to improvements for patients with osteosarcoma in more than 30 years. On the basis of our growing understanding of metastasis biology, it is now reasonable and essential that we focus on developing therapeutics that target metastatic progression...
August 15, 2014: Clinical Cancer Research